A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 467 participants.

Also called NCT01590797

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 467 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01590797
Other papers using this trial's data
  • Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes Journal of diabetes investigation, 2017-05 DOI, PubMed 27740719, PMC5415484 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01590797. Randomized; triple masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2014-06-11 (actual). Results posted on 2015-01-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Intervention (Biological)
Insulin
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01590797
Content hash
56438dc20607370532e5f54473785cb2a49e37a039d975aa8a6ac66ed95549f9